2024
Airway Esophageal Fistula
Koch K, Dhanasopon A, Woodard G. Airway Esophageal Fistula. Thoracic Surgery Clinics 2024, 34: 405-414. PMID: 39332865, DOI: 10.1016/j.thorsurg.2024.07.005.Peer-Reviewed Original ResearchConceptsTracheoesophageal fistulaManagement of tracheoesophageal fistulaTreating tracheoesophageal fistulaAcquired tracheoesophageal fistulaFistula tractDefinitive treatmentSurgical repairSurgical approachSurgical methodsPrevent recurrenceMuscle flapTracheal stentPathological connectionIntensive careImprove outcomesFistulaDiagnostic toolRepairEsophagealRecurrenceEsophagusStentFlapFurther insights into MARS 2
Zhan P, Boffa D, Woodard G. Further insights into MARS 2. The Lancet Respiratory Medicine 2024, 12: e52. PMID: 39214641, DOI: 10.1016/s2213-2600(24)00251-0.Peer-Reviewed Original ResearchShades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
Woodard G, Jablons D. Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs? Journal Of Thoracic Oncology 2024, 19: 1135-1137. PMID: 39111999, DOI: 10.1016/j.jtho.2024.06.007.Peer-Reviewed Original ResearchShould the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
Woodard G, Dacic S. Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors? Journal Of Thoracic Oncology 2024, 19: 663-665. PMID: 38719420, DOI: 10.1016/j.jtho.2024.01.004.Peer-Reviewed Original Research
2023
Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis?
Woodard G, Cho C, Chen L. Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis? Annals Of Surgical Oncology 2023, 31: 25-27. PMID: 37899411, DOI: 10.1245/s10434-023-14388-1.Peer-Reviewed Original ResearchComparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas
Woodard G, Ding V, Cho C, Brand N, Kratz J, Jones K, Jablons D. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Lung Cancer 2023, 180: 107211. PMID: 37121213, PMCID: PMC10900430, DOI: 10.1016/j.lungcan.2023.107211.Peer-Reviewed Original ResearchConceptsInvasive portionDriver mutationsSolid adenocarcinomaLung cancer driver mutationsNext-generation sequencingWarrants further studyLobar resectionClinical characteristicsSurgical databaseAsian patientsInvasive cancerPoor prognosisLung cancerLung lesionsInvasive componentInvasive solid tumorsNormal lungLepidicStage IPromising biomarkerSolid tumorsCancer developmentSame time periodGenes SPP1Gene expressionThe Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
Grant M, Woodard G, Goldberg S. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 513-531. PMID: 37024389, DOI: 10.1016/j.hoc.2023.02.003.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerMetastatic non-small cell lung cancerResectable non-small cell lung cancerImmuno-oncology agentsHistologic classification systemUnited States FoodResectable tumorsSystemic therapyDriver alterationsDrug AdministrationStates FoodSystemic managementPatientsTherapyCancerEvolving roleClassification systemNTRKHER2TumorsKRASEGFRBRAF
2022
Thoracic CT follow-up after non-small-cell lung cancer resection
Woodard G, Boffa D, Blasberg J. Thoracic CT follow-up after non-small-cell lung cancer resection. The Lancet Oncology 2022, 23: e484. PMID: 36328013, DOI: 10.1016/s1470-2045(22)00618-0.Commentaries, Editorials and LettersCould Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?
Woodard GA, Cho C, Chen L. Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response? Journal Of Thoracic Oncology 2022, 17: 592-595. PMID: 35465963, DOI: 10.1016/j.jtho.2022.03.009.Peer-Reviewed Original Research
2021
Discovering dominant tumor immune archetypes in a pan-cancer census
Combes A, Samad B, Tsui J, Chew N, Yan P, Reeder G, Kushnoor D, Shen A, Davidson B, Barczak A, Adkisson M, Edwards A, Naser M, Barry K, Courau T, Hammoudi T, Argüello R, Rao A, Olshen A, Consortium T, Spitzer M, Fong L, Nelson A, Kumar R, Lee J, Burra A, Hsu J, Hackett C, Tolentino K, Sjarif J, Johnson P, Shao E, Abrau D, Lupin L, Shaw C, Collins Z, Lea T, Corvera C, Nakakura E, Carnevale J, Alvarado M, Loo K, Chen L, Chow M, Grandis J, Ryan W, El-Sayed I, Jablons D, Woodard G, Meng M, Porten S, Okada H, Tempero M, Ko A, Kirkwood K, Vandenberg S, Guevarra D, Oropeza E, Cyr C, Glenn P, Bolen J, Morton A, Eckalbar W, Cai C, Zhan J, Davis K, Kelley R, Chapman J, Atreya C, Patel A, Daud A, Ha P, Diaz A, Kratz J, Collisson E, Fragiadakis G, Erle D, Boissonnas A, Asthana S, Chan V, Krummel M. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell 2021, 185: 184-203.e19. PMID: 34963056, PMCID: PMC8862608, DOI: 10.1016/j.cell.2021.12.004.Peer-Reviewed Original ResearchConceptsTumor immune microenvironmentIndividual tumorsTumor gene expression patternsCancer immunityImmune microenvironmentImmune compositionImmune systemTumor biologyUnique immuneTissue of originFlow cytometryCancer typesDriver mutationsImmune organizationDominant patternStandardized protocolTumorsSignificant heterogeneityCancerUniversity of CaliforniaTissueGene expression patternsCommon patternTherapyImmuneImproved outcomes and staging in non-small-cell lung cancer guided by a molecular assay
Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. Future Oncology 2021, 17: 4785-4795. PMID: 34435876, PMCID: PMC9039775, DOI: 10.2217/fon-2021-0517.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinogenesisCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantClinical Decision-MakingDatasets as TopicDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsMolecular Diagnostic TechniquesNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyProspective StudiesReal-Time Polymerase Chain ReactionRisk AssessmentConceptsCell lung cancerUndetectable metastasesLung cancerCell lung cancer patientsDisease-free survivalAdjuvant chemotherapy decisionsTime of surgeryLung cancer patientsSurgical resectionComplete resectionProspective studyCancer patientsChemotherapy decisionsResectionMolecular assaysPatientsPredictive benefitMetastasisCancerMortalityQuantitative PCRExpression profilesEarly stagesAssaysSurgeryMolecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy
Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer 2021, 22: 587-595. PMID: 34544620, DOI: 10.1016/j.cllc.2021.08.008.Peer-Reviewed Original ResearchConceptsMolecular risk stratificationAdjuvant chemotherapyDisease-free survivalEGFR mutation statusAdjuvant interventionRisk stratificationEGFR patientsNSCLC patientsEGFR statusMutation statusSmall cell lung cancer patientsNon-squamous NSCLC patientsCell lung cancer patientsStage IA NSCLCStage IB patientsThird-generation TKIsEarly-stage NSCLCNon-Squamous NonLung cancer patientsEarly-stage cohortIB patientsProspective studyResidual diseaseCancer patientsEGFR mutationsRole of adjuvant therapy in T1-2N0 resected non–small cell lung cancer
Woodard GA, Li A, Boffa DJ. Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2021, 163: 1685-1692. PMID: 34334172, DOI: 10.1016/j.jtcvs.2021.05.053.Peer-Reviewed Original ResearchResectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity
Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity. Annals Of Surgical Oncology 2021, 28: 4953-4959. PMID: 33728541, DOI: 10.1245/s10434-021-09757-7.Peer-Reviewed Original ResearchConceptsSingle-institution reviewInstitution reviewFibrous tumorThoracic cavityLong-term survival dataGiant solitary fibrous tumorBackgroundSolitary fibrous tumorsKaplan-Meier analysisPredictors of recurrenceRare mesenchymal tumorLong-term outcomesRisk of recurrenceMajority of tumorsSolitary fibrous tumorLong-term survivalSFT recurrencePathologic characteristicsRisk stratificationTumor sizeMesenchymal tumorsRisk factorsTumor necrosisVisceral pleuraClinical informationRecurrence
2020
Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma
Yang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H. Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. Experimental Lung Research 2020, 47: 9-25. PMID: 33107354, DOI: 10.1080/01902148.2020.1836691.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaPonatinib treatmentPleural mesotheliomaMPM linesTherapeutic approachesPotential therapeutic approachExpression levelsNew therapeutic strategiesHuman MPM cellsMPM therapyPSTAT5 levelsWestern blot analysisMPM patientsMPM treatmentDeadly malignancyLevels of γH2AXPotential utilityTherapeutic strategiesTumor growthMPM cellsPathway inhibitionTumor modelPonatinibActivation of AblTumor samples
2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance indexCase report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass
Woodard GA, Lee H, Fels Elliott DR, Jones KD, Wong J, Jablons DM, Ihnken K. Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass. Journal Of Cardiothoracic Surgery 2019, 14: 158. PMID: 31488186, PMCID: PMC6728940, DOI: 10.1186/s13019-019-0980-1.Peer-Reviewed Original ResearchConceptsLeft internal mammary arteryDissection bedEstrogen receptorBreast cancerChest radiationHormonal therapyBypass surgeryRecurrent cancerNon-ST elevation myocardial infarctionCoronary artery bypass surgeryRecurrent metastatic breast cancerThree-vessel coronary artery bypassTumor cellsBreast intraductal carcinomaPrior chest radiationCoronary artery bypassArtery bypass surgeryInternal mammary arteryRecurrent breast cancerSaphenous vein graftsElevation myocardial infarctionMetastatic breast cancerHistory of cancerAreas of necrosisDense fibrous tissueMesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley‐Bosco E, Galateau‐Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA A Cancer Journal For Clinicians 2019, 69: 402-429. PMID: 31283845, PMCID: PMC8192079, DOI: 10.3322/caac.21572.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalAsbestosAustraliaBiomarkers, TumorCarcinogenesisCombined Modality TherapyDiagnostic ErrorsEuropeGenetic Predisposition to DiseaseGerm-Line MutationGlobal Burden of DiseaseHumansIncidenceInhalation ExposureInternational CooperationMesotheliomaMolecular Targeted TherapyOccupational ExposurePleuraPleural NeoplasmsPneumonectomyPrognosisTumor Suppressor ProteinsUbiquitin ThiolesteraseUnited StatesConceptsNovel systemic treatmentsRole of surgeryKey pathogenic mechanismsAccuracy of diagnosisAggressive managementSystemic treatmentLocal therapyPeritoneal mesotheliomaPleural mesotheliomaMesothelioma incidenceIncidence rateTreatment outcomesProtein 1 mutationImmune responseGermline BRCA1Epidemiological studiesMortality ratePathogenic mechanismsMesotheliomaMesothelioma diagnosisUse of asbestosInadequate treatmentOlder individualsOlder peopleEarly detectionIncorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging
Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging. Journal Of Thoracic Oncology 2019, 14: 1223-1232. PMID: 30959120, DOI: 10.1016/j.jtho.2019.03.015.Peer-Reviewed Original Research
2018
Cast of the Right Bronchial Tree
Woodard GA, Wieselthaler GM. Cast of the Right Bronchial Tree. New England Journal Of Medicine 2018, 379: 2151-2151. PMID: 30485771, DOI: 10.1056/nejmicm1806493.Peer-Reviewed Original Research